Coloplast A/S stock sinks nearly 8% as Medicare reimbursement change hits Kerecis outlook
Shares of Coloplast A/S dropped almost 8% on Nasdaq Copenhagen Friday following a cut in its growth forecast for Kerecis, now expected to be about 10%, down from around 25%. The company blamed new U.S. Medicare reimbursement rules for the setback. By 13:07 CET, Coloplast B had slid 7.82% to 495.35 Danish crowns.